-transparent.png){kind=logo}
Fluconazole is a recently developed triazole with activity in vitro against Cryptococcus neoformans, water solubility, and excellent oral absorption. We compared fluconazole in murine cryptococcosis with ketoconazole and amphotericin B. Fluconazole was highly effective in suppressing cryptococcosis in mice challenged by the intravenous and intranasal routes, and was comparable with the other two drugs in its protective capacity. However, fluconazole was superior to ketoconazole and comparable with amphotericin B after intracerebral challenge. Fluconazole may warrant clinical evaluation in cryptococcosis.
Related Publications
E Palou de Fernandez, and
M M Patino, and
J R Graybill, and
M H Tarbit
June 1991,
Lakartidningen,
E Palou de Fernandez, and
M M Patino, and
J R Graybill, and
M H Tarbit
January 1988,
Scandinavian journal of infectious diseases,
E Palou de Fernandez, and
M M Patino, and
J R Graybill, and
M H Tarbit
May 1987,
Annals of internal medicine,
E Palou de Fernandez, and
M M Patino, and
J R Graybill, and
M H Tarbit
June 2003,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
E Palou de Fernandez, and
M M Patino, and
J R Graybill, and
M H Tarbit
January 1989,
Annals of internal medicine,
E Palou de Fernandez, and
M M Patino, and
J R Graybill, and
M H Tarbit
January 1989,
Diagnostic microbiology and infectious disease,
E Palou de Fernandez, and
M M Patino, and
J R Graybill, and
M H Tarbit
June 1992,
The New England journal of medicine,
E Palou de Fernandez, and
M M Patino, and
J R Graybill, and
M H Tarbit
June 1992,
The New England journal of medicine,
E Palou de Fernandez, and
M M Patino, and
J R Graybill, and
M H Tarbit
June 1992,
The New England journal of medicine,
E Palou de Fernandez, and
M M Patino, and
J R Graybill, and
M H Tarbit
October 1994,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
